Tango Therapeutics
Founded 2020 · CIK 0001819133 · Biotech · Public
Synthetic lethality platform identifying cancer drug targets and developing therapeutics like vopimetostat
tangotx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $95M
- 2 Form D · Oct 2025
- 11 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 8 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $80,016,604 | |
| Private capital raised | Form D · SEC | $14,999,995 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2832 | Arena Pharmaceuticals | — | $187M |
| 2833 | Prelude Therapeutics | — | $97M |
| 2834 | Coriell Life Sciences, Inc. | — | $10M |
| 2835 | Tango Therapeutics | — | $95M |
| 2836 | Arcutis Biotherapeutics, Inc. | — | $94M |
| 2837 | OMNI BIO PHARMACEUTICAL, INC. | — | $28M |
| 2838 | ReAlta Life Sciences, Inc. | — | $94M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Douglas BarryExecutive Officer
- Daniella BeckmanExecutive Officer
- Alexis BorisyDirector
- Lesley CalhounDirector
- Adam CrystalExecutive Officer
- Aaron DavisDirector
- Alan HuangExecutive Officer
- Reid HuberDirector
- John KetchumDirector
- Malte PetersDirector
- Kanishka PothulaDirector
- Mace RothenbergDirector
- Barbara WeberDirector · Executive Officer
Patents
- Compounds And Methods Of Useapplication
- An Hdac Inhibitor For Treating Cancer With A Modified STK11 Activity Or Expressionapplication
- Compounds And Methods Of Useapplication
- Compounds And Methods Of Usegranted
- Compounds And Methods Of Useapplication
- Compounds And Methods Of Useapplication
- Compounds And Methods Of Usegranted
- Compounds And Methods Of Useapplication
- Hdac Inhibitors And Therapeutic Use Thereofapplication
- Compounds And Methods Of Usegranted
- Novel Modulators Of EHMT1 And EHMT2 And Therapeutic Use Thereofapplication
- Novel Hdac Inhibitors And Therapeutic Use Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.